Serum levels of per- and poly-fluoroalkyl substances among middle-aged and elderly populations in Beijing and their association with dyslipidemia
Food and Chemical Toxicology · 2024-11 · 193 · 115066
DOI: 10.1016/j.fct.2024.115066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2024-11. Verfasst von Lan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Capital Medical University, Beijing, 100069, China; Beijing Key Laboratory of Diagnostic and Traceability Technologies for F…. Hauptthemen laut MEDLINE: Fluorocarbons, Dyslipidemias, Alkanesulfonic Acids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Per- and poly-fluoroalkyl substances (PFAS), ubiquitous environmental pollutants, have been reported as possible contributors to human dyslipidemia. However, evidence for emerging PFAS remains scarce. Using a nested case-control study (n = 357) in a middle-aged and elderly population from Beijing, we investigated the serum concentrations of eight traditional and fourteen emerging PFAS and their potential links with dyslipidemia. Perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) were found to be the dominant PFAS. Serum levels of perfluorohexanesulfonic acid (PFHxS) and 6:2 chlorinated polyfluoroalkyl ether sulfonate (6:2 Cl-PFESA/F53B) were associated with higher risk of elevated low-density lipoprotein cholesterol (LDL-C) with odds ratios (OR) of 3.88 (95% CI: 1.44-10.51) and 2.71 (95% CI: 1.11-6.57), respectively. These compounds also positively correlated with high total cholesterol (TC). PFOA, perfluorodecanoic acid (PFDA), and 6:2 Fluorotelomer phosphate monoester (6:2 PAP) were linked to increased risk of high triglycerides (TG) with OR of 2.79 (95% CI: 1.30-6.01), 2.41 (95% CI: 1.27-4.60), and 1.53 (95% CI: 1.05-2.22), respectively. Conversely, perfluorooctane sulfonamidoacetic acid (FOSAA) was negatively associated with high TG levels. These findings indicate that both traditional and emerging PFAS may induce dyslipidemia, emphasizing the potentially serious impact of emerging PFAS on human health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Capital Medical University, Beijing, 100069, China; Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beij…
- Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beijing, 100013, China.
- Department of Medical Science and Technology, Guiyang Healthcare Vocational University, Guiyang, China. Electronic address: zhongnan0911@126.com.
- Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beijing, 100013, China. Electronic address: ligang@bjcdc.org.
Zitieren
APA
Zhang, L., Du, J., Guo, Q., Xu, X., Li, H., Zhong, N., Zhang, J., Li, G., & Shao, B. (2024). Serum levels of per- and poly-fluoroalkyl substances among middle-aged and elderly populations in Beijing and their association with dyslipidemia. Food and Chemical Toxicology, 193, 115066. https://doi.org/10.1016/j.fct.2024.115066
Vancouver
Zhang L, Du J, Guo Q, Xu X, Li H, Zhong N, et al. Serum levels of per- and poly-fluoroalkyl substances among middle-aged and elderly populations in Beijing and their association with dyslipidemia. Food and Chemical Toxicology. 2024;193:115066. doi:10.1016/j.fct.2024.115066
BibTeX
@article{Zhang2024,
author = {Zhang, Lan and Du, Jing and Guo, Qiaozhen and Xu, Xin and Li, Hong and Zhong, Nannan and Zhang, Jing and Li, Gang and Shao, Bing},
title = {Serum levels of per- and poly-fluoroalkyl substances among middle-aged and elderly populations in Beijing and their association with dyslipidemia},
journal = {Food and Chemical Toxicology},
year = {2024},
volume = {193},
pages = {115066},
doi = {10.1016/j.fct.2024.115066}
}
EUVIMED